

AD _____

Award Number: DAMD17-02-1-0354

TITLE: Association Between Offspring's hCG Genotype and Breast Cancer Risk in Mothers: A Novel Approach

PRINCIPAL INVESTIGATOR: Habibul Ahsan, M.D.

CONTRACTING ORGANIZATION: Columbia University in the
City of New York
New York, New York 10032-3702

REPORT DATE: June 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050407 160

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2004	3. REPORT TYPE AND DATES COVERED Annual (24 May 03 - 23 May 04)	
4. TITLE AND SUBTITLE Association Between Offspring's hCG Genotype and Breast Cancer Risk in Mothers: A Novel Approach			5. FUNDING NUMBERS DAMD17-02-1-0354	
6. AUTHOR(S) Habibul Ahsan, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Columbia University in the City of New York New York, New York 10032-3702 E-Mail: ha37@columbia.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) We proposed to examine the novel hypothesis that the hCG genotype of a woman's offspring is associated with her breast cancer risk. Using the existing Metropolitan New York Registry (MNYR) resources, a case-control study was designed to examine the hypothesis whether first-born offspring's hCG β 5 genotype (i.e., placental hCG β 5 genotype during first FTP) is associated with a woman's breast cancer risk. To date, the three tasks in the approved Statement of Work for year 1 have been accomplished, and we are in the process of laboratory analyses.				
14. SUBJECT TERMS None provided			15. NUMBER OF PAGES 5	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified		20. LIMITATION OF ABSTRACT Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	4
Reportable Outcomes.....	5
Conclusions.....	5
References.....	5
Appendices.....	5

INTRODUCTION:

It has long been known that both early age at first birth and total number of full-term pregnancies (FTPs) reduce breast cancer risk¹⁻⁵. The underlying biology of this protection is yet to be clearly known. One or more of the hormonal changes during pregnancy are the logical candidates for this effect. Based on the published animal, human and epidemiological data, human chorionic gonadotropin (hCG), a glycoprotein hormone exclusively produced during pregnancy by the fetal part of placenta, has emerged as the most promising candidate^{6,7}. The level of protection conferred by FTP may not be the same for all women, suggesting that there may be inherent variability in the protective effect across individuals. The hCG genes are well-known. Of the three trophoblastic hCG genes, hCG β 5 is the most expressed gene in placenta, most highly conserved and the major contributor of hCG function during pregnancy^{8,9}. The genotype of the fetal placenta is actually the genotype of the developing fetus. We proposed to examine the novel hypothesis that *the hCG genotype of a woman's offspring is associated with her breast cancer risk*. The data and biospecimens for this study are banked in the repository of the Metropolitan New York Registry (MNYR), one of six collaborating sites of the NCI funded Cooperative Family Registry for Breast Cancer Studies (CFRBCS). Since 1995, MNYR assembled 1,150 families with more than 3,500 individuals. Using the existing MNYR resources, a case-control study was designed to examine the hypothesis whether first-born offspring's hCG β 5 genotype (i.e., placental hCG β 5 genotype during first FTP) is associated with a woman's breast cancer risk. We proposed to evaluate our hypothesis by comparing the hCG β 5 genotypes of first-born children of women with breast cancer (cases) and women without breast cancer (controls).

BODY:

This is the annual report for year 2 of the study. We have aimed to finish tasks 4-6 listed below during year 2 in the approved Statement of Work. To date, all three tasks for year 1 have been accomplished, and we are in the process of laboratory analyses. Questionnaire data on all participants are currently maintained in a relational database in Access which undergoes continuous quality-control checks. For the proposed study, a separate database specific for this project has been created containing all relevant data. Standard data cleaning and editing have been performed on these data to ensure that the case-control status, the relationship between the cases and controls and their first-born children, and the relevant risk factor information are accurate and consistent.

KEY RESEARCH ACCOMPLISHMENTS:

Year 1

Task 1: Identification of 1,106 eligible breast cancer cases and unaffected controls and their first-born children in MNYR database who are eligible for the study.

Task 2: Cleaning and editing of the questionnaire and family history data on the eligible study participants.

Task 3: Obtaining the DNA samples from the MNYR biospecimen bank on the 1,106 eligible study participants.

Year 2

Task 4: Genotyping 1,106 samples for the four SNPs in hCG β 5 gene using fluorescent polarization technique in 96 micro-well plate format.

Task 5: Cleaning and editing of the laboratory data

Task 6: Combining questionnaire and family history data with the laboratory data

REPORTABLE OUTCOMES:

Not applicable

CONCLUSIONS:

We have accomplished the three tasks in the approved Statement of Work for year 1 as planned and we are in the process of laboratory genotyping analyses. All tasks for year 1-2 should be accomplished the end of 2004.

REFERENCES:

1. MacMahon B, Purde M, Cramer D, Hint E. Association of breast cancer risk with age at first and subsequent births: a study in the population of the Estonian Republic. *J.Natl.Cancer Inst.* 1982;69:1035-38.
2. Trichopoulos D, Hsieh CC, MacMahon B, Lin TM, Lowe CR, Mirra AP *et al.* Age at any birth and breast cancer risk. *Int.J.Cancer* 1983;31:701-04.
3. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. *Epidemiol.Rev.* 1993;15:36-47.
4. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study. *Am.J.Epidemiol.* 1994;139:819-35.
5. Chie WC, Hsieh C, Newcomb PA, Longnecker MP, Mittendorf R, Greenberg ER *et al.* Age at any full-term pregnancy and breast cancer risk. *Am.J.Epidemiol.* 2000;151:715-22.
6. Russo IH, Russo J. Hormonal approach to breast cancer prevention. *J.Cell.Biochem.* 2000;34:1-6.
7. Rao ChV. Does full-term pregnancy at a young age protect women against breast cancer through HCG? *Gynecol.* 2000;96:783-86.
8. A.K.Miller-Lindholm, E.Bedows, C.F.Bartels, J.Ramey, V.Maclin, R.W.Ruddon, A naturally occurring genetic variant in the human chorionic gonadotropin-beta gene 5 is assembly inefficient. *Endocrinology* 140 (1999) 3496-3506.
9. A.K.Miller-Lindholm, C.J.LaBenz, J.Ramey, E.Bedows, R.W.Ruddon, Human chorionic gonadotropin-beta gene expression in first trimester placenta. *Endocrinology* 138 (1997) 5459-5465.

APPENDICES:

Not applicable